Spotlight Growth
No Result
View All Result
Wednesday, February 8, 2023
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener
No Result
View All Result
No Result
View All Result
Home Bio/Med/Pharma

3 Microcap Stocks with Pending FDA Approvals

by admin
June 28, 2018
in Bio/Med/Pharma, Opinion
0
3 Microcap Stocks with Pending FDA Approvals

Three Microcaps Facing FDA Drug Decisions Later This Year Opinion

Stocks that receive approval from the FDA for their new drugs can often rocket to new highs. These three microcaps have upcoming PDUFA (Prescription Drug User Fee Act) dates that will impact their underlying stocks.

Tetraphase Pharmaceuticals, Inc. (NASDAQ: TTPH) learned earlier this year what it’s like to have the FDA not approve your crown jewel drug. The stock had traded as high as $9.93 last year before dropping to almost $2 on the negative FDA news.

Source: FinViz.com
Source: FinViz.com

The company now has a new date, and new hope, for it’s  once-daily intravenous (IV) eravacycline drug, designed for hard-to-treat urinary tract infections. The FDA is reviewing the drug and has set a tentative date of August 28, 2018 for a decision.

On June 11th the company presented positive data on two trials of the drug that it had conducted. CEO and President of Tetraphase Pharmaceuticals, Guy MacDonald, stated they were “pleased to show that favorable clinical and microbiological responses were observed for eravacycline…” Holders of the stock will be rewarded if these favorable responses carry through to FDA approval.

EyePoint Pharmaceuticals (NASDAQ: EYPT) is developing sustained release products to treat retinal diseases and other eye conditions. The company has a November 5, 2018 PDUFA for it’s Durasert and Durasert micro-insert products.

The Durasert product is already marketed in the U.K, Germany and Portugal, and is awaiting approval in 13 other countries in addition to the United States.

Source: FinViz.com
Source: FinViz.com

The product is superior to others on the market in that it treats a hard to reach areas of the eye, where for certain conditions, medicine must be delivered on a regular basis.

Instead of eye injections every few months, the Durasert product is inserted and delivers the needed medicine without injections. If EYPT receives FDA approval in November the stock’s investors may be “eyeing” a hefty profit.

Trevena, Inc. (NASDAQ: TRVN) develops pain relievers for moderate-to-severe acute pain, such as that associated with a migraine.

Trevena’s  Oliceridine injection has been designated a Breakthrough Therapy by the FDA, and has a PDUFA date of November 2, 2018.

Source: FinViz.com
Source: FinViz.com

The stock has been range bound this year, trading between $1.50 and $2.30. With the stock trading in the $1.60s, now may be a good time to establish a position.

The company also recently added three experienced marketing and medical affairs members to their staff, perhaps in anticipation of getting an approved drug into patient’s hands.

FDA approval of their product may positively impact one or more of these microcaps in the next few months. Taking a position now may prove to be a prudent investment headed into year-end.

Disclaimer: The author and Spotlight Growth has no positions in any of the stocks mentioned in this article. Nor does either party currently have any relationship, or any other conflicts of interest, with any of the companies mentioned in this article. This content is meant for informational and entertainment purposes only and should not be meant as a recommendation to buy or sell any securities. Please visit a licensed financial representative to determine what investments are right for you.

Article By: Steven Adams

Tags: acquisitionbiopharmaceuticalsbiotechclinical trialscommon stockdrug approvalemerging growthFDAinvestmentlabmanufacturingmedicalMergermicrocap stocksmicrocapsNASDAQnewsopinionpharmaceuticalspublic companysalesservicessmall cap companiessmall cap stockssmall capsSpotlight GrowthSpotlight Growth Stockstreatment
  • Trending
  • Comments
  • Latest
Asure Software NASDAQ ASUR Human Capital Management HCM Industry Spotlight Growth

Asure Software (NASDAQ: ASUR) is Expanding to Meet the Rising Demand for Human Capital Management Software

September 27, 2022
OLB Group NASDAQ OLB Cuentas NASDAQ CUEN Partnership Fintech Spotlight Growth

OLB Group (NASDAQ: OLB) and Cuentas (NASDAQ: CUEN) Team Up to Bring Fintech Solutions to Over 32,000 Bodegas Across the United States

October 6, 2022
Siyata Mobile NASDAQ SYTA SYTAW SD7 VK7 Purchase Orders Spotlight Growth

New Purchase Orders for SD7 Rugged Device, VK7, and Other Accessories Boost Siyata Mobile’s Outlook (NASDAQ: SYTA)

December 14, 2021
Telcoin TEL Crypto Spotlight Growth

Telcoin (TEL) Quietly Leads a Crypto Remittance Revolution

June 15, 2021
Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

Cybersecurity Stocks Coming Into Focus Amid High-Profile Attacks

0
Safe-T SFET NASDAQ UN Presentation

Safe-T (NASDAQ: SFET) Has Been Selected to Present at the United Nations’ Office of Information and Communications Technology Event

0
Safe-T Group SFET Q4 FY 2020 Financial Results

Safe-T Group (NASDAQ: SFET) Reports Fourth Quarter and Full Year 2020 Financial Results

0
Safe-T Group NASDAQ SFET FY 2020 Prelim

Safe-T Group Ltd. (NASDAQ: SFET) Estimates Record-High Annual Revenues of Approximately $4.9 Million Representing ~50% Growth YoY 2020

0
Innovative Eyewear NASDAQ LUCY Lucyd Lyte 2 Smart Glasses Spotlight Growth

Innovative Eyewear (NASDAQ: LUCY) Debuts Lucyd Lyte 2.0 Audio Eyewear Product

February 7, 2023
American Resources Corporation NASDAQ AREC Reduced Debt By 9 Million Spotlight Growth

American Resources Corporation (NASDAQ: AREC) Reduces Debt by Over $9 Million

February 7, 2023
Its All Greek to Me What Are Option Greeks Spotlight Growth

It’s All Greek to Me: What Are Option Greeks and How Do They Impact Traders?

February 6, 2023
Unleashing the Power of 5G The Future of Mobile Technology Spotlight Growth

Unleashing the Power of 5G: The Future of Mobile Technology

February 6, 2023

Recent News

Innovative Eyewear NASDAQ LUCY Lucyd Lyte 2 Smart Glasses Spotlight Growth

Innovative Eyewear (NASDAQ: LUCY) Debuts Lucyd Lyte 2.0 Audio Eyewear Product

February 7, 2023
American Resources Corporation NASDAQ AREC Reduced Debt By 9 Million Spotlight Growth

American Resources Corporation (NASDAQ: AREC) Reduces Debt by Over $9 Million

February 7, 2023

Categories

  • Bio/Med/Pharma
  • Cannabis
  • Commodities
  • Consumer Goods
  • Crowdfunding
  • Crypto Cheat Sheets
  • Cryptocurrency
  • Earnings
  • Education
  • Entertainment
  • Financials
  • Market News
  • Opinion
  • Politics
  • Real Estate
  • Split Watch
  • Sponsored
  • Store
  • Technology
  • Uncategorized
  • Venture Capital/Private Equity (VC/PE)

Site Navigation

  • Disclosures
  • Terms Of Service
  • Privacy Policy
  • Contact Us

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

No Result
View All Result
  • Home
  • News
    • Bio/Med/Pharma
    • Cannabis
    • Commodities
    • Consumer Goods
    • Crowdfunding
    • Cryptocurrency
    • Crypto Cheat Sheets
    • Earnings
    • Entertainment
    • Financials
    • Market News
    • Opinion
    • Politics
    • Technology
    • Venture Capital/Private Equity (VC/PE)
  • Video
  • Stock and Crypto Screener

Copyright © 2017-2022 Spotlight Growth. All Right Reserved. Designed by Cool Cat Interactive.

Newsletter Signup

Subscribe to our weekly newsletter below and never miss the latest small/micro-cap analysis and investment news from Spotlight Growth.

Enter your email address

Thanks, I’m not interested